Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $58.11 Consensus Target Price from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has earned an average rating of “Buy” from the fourteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $58.1111.

Several equities analysts have recently issued reports on TERN shares. BMO Capital Markets boosted their price target on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Jefferies Financial Group reiterated a “buy” rating and set a $70.00 price objective on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. William Blair upgraded Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, November 3rd. Finally, HC Wainwright raised their price target on Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, December 9th.

Terns Pharmaceuticals Trading Up 4.2%

NASDAQ:TERN opened at $40.86 on Thursday. The firm has a market capitalization of $4.24 billion, a PE ratio of -39.67 and a beta of -0.28. Terns Pharmaceuticals has a 52 week low of $1.87 and a 52 week high of $48.26. The stock has a 50 day moving average of $38.19 and a 200-day moving average of $22.78.

Insider Buying and Selling at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the sale, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $39.19, for a total transaction of $571,507.77. Following the sale, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at $11,324,969.44. This represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 155,826 shares of company stock valued at $5,882,597. Insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds have recently modified their holdings of TERN. Cubist Systematic Strategies LLC grew its stake in Terns Pharmaceuticals by 136.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock valued at $78,000 after acquiring an additional 16,363 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Terns Pharmaceuticals during the first quarter worth approximately $51,000. Goldman Sachs Group Inc. boosted its holdings in shares of Terns Pharmaceuticals by 21.0% during the first quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company’s stock worth $1,145,000 after purchasing an additional 71,971 shares during the period. Geode Capital Management LLC grew its position in Terns Pharmaceuticals by 3.8% during the second quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after purchasing an additional 59,145 shares in the last quarter. Finally, Candriam S.C.A. increased its stake in Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after buying an additional 214,266 shares during the period. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.